| 中文名称 | 炔诺孕酮 |
| 英文名称 | Norgestrel |
| CAS号 | 6533-00-2 |
| 分子式 | C21H28O2 |
| 分子量 | 312.45 |
| EINECS号 | 229-433-5 |
| 熔点 | 239-241 °C(lit.) |
| 沸点 | 392.36°C (rough estimate) |
| 密度 | 1.0697 (rough estimate) |
| 折射率 | 1.4900 (estimate) |
| 溶解度 | 氯仿(少量,超声处理)、二氯甲烷(少量溶解)、甲醇(少量溶解) |
| 形态 | 固体 |
| 酸度系数(pKa) | 13.09±0.40(Predicted) |
| 颜色 | 乙醚-己烷溶液中结晶的晶体 |
| 危险品标志 | Xn |
| 危险类别码 | 20/21/22-40 |
| 安全说明 | 22-36 |
| WGK Germany | 3 |
| RTECS号 | JF8259000 |
| 海关编码 | 2937230000 |
| 毒害物质数据 | 6533-00-2(Hazardous Substances Data) |
| 毒性 | LD50 oral in rat: 5010mg/kg |
Norgestrel (20 µM; 24 hours; 661W cells) treatment significantly increases cellular viability after serum deprivation and so it is demonstrated that Norgestrel is neuroprotective to stressed 661W cells.
Norgestrel (20 µM; 24 hours; 661W cells) treatment decreases apoptotic induced cleavage of PARP and caspase-3.
Norgestrel (20 µM; 6 hours; 661W cells) treatment bFGF is results in a significant upregulation of bFGF mRNA in photoreceptor cells.
Cell Viability Assay
| Cell Line: | 661W cells |
| Concentration: | 20 µM |
| Incubation Time: | 24 hours |
| Result: | Significantly increased cellular viability after serum deprivation. |
Western Blot Analysis
| Cell Line: | 661W cells |
| Concentration: | 20 µM |
| Incubation Time: | 24 hours |
| Result: | Decreased apoptotic induced cleavage of PARP and caspase-3. |
RT-PCR
| Cell Line: | 661W cells |
| Concentration: | 20 µM |
| Incubation Time: | 6 hours |
| Result: | A significant upregulation of bFGF mRNA over 1 hour. |
Norgestrel (100 mg/kg; intraperitoneal injection; for 6, 24 or 48 hours; Balb/c mice) treatment can prevent light-induced ROS in photoreceptor cells, and subsequent cell death. Norgestrel acts via post-translational modulation of the major antioxidant transcription factor Nrf2; bringing about its phosphorylation, subsequent nuclear translocation, and increases levels of its effector protein superoxide dismutase 2 (SOD 2 ).
| Animal Model: | Balb/c mice are born into and maintained in dim cyclic light |
| Dosage: | 100 mg/kg; |
| Administration: | Intraperitoneal injection; for 6, 24 or 48 hours |
| Result: | Increased expression and activation of Nrf2 via phosphorylation on serine 40, increased expression of its target antioxidant superoxide dismutase 2 (SOD 2 ), and reduced mitochondrial oxidative stress. |